Company intelligence / Profile preview

Osteopore

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

Osteopore has commercialized 3D-printed, bioresorbable polymer scaffolds for bone and tissue regeneration, used in over 80,000 successful cases and approved in 25+ countries, with active new clinical studies in knee cartilage, tendon, and veterinary markets.[1][4]

Therapeutic areas: OtherNeurologyRheumatology
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Implantable Medical Devices

Partnerships

Accelerate Technologies (A*STAR, Singapore)National Dental Centre Singapore (NDCS)Livingstone HealthCellHeal (China)University of Chile

Beyond the preview

Go deeper on Osteopore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osteopore.

Explore the full profile